Cytokinetics Statistics
Share Statistics
Cytokinetics has 118.01M shares outstanding. The number of shares has increased by 14.57% in one year.
| Shares Outstanding | 118.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 113.56M |
| Failed to Deliver (FTD) Shares | 102 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 13.73M, so 11.63% of the outstanding shares have been sold short.
| Short Interest | 13.73M |
| Short % of Shares Out | 11.63% |
| Short % of Float | 12.09% |
| Short Ratio (days to cover) | 11.37 |
Valuation Ratios
The PE ratio is -15.31 and the forward PE ratio is -10.42.
| PE Ratio | -15.31 |
| Forward PE | -10.42 |
| PS Ratio | 1070.22 |
| Forward PS | 17.5 |
| PB Ratio | -20.86 |
| P/FCF Ratio | -19.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Cytokinetics has an Enterprise Value (EV) of 8.70B.
| EV / Earnings | -16.53 |
| EV / Sales | 1155.53 |
| EV / EBITDA | -19.05 |
| EV / EBIT | -17.54 |
| EV / FCF | -20.93 |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of -1.6.
| Current Ratio | 6.12 |
| Quick Ratio | 6.12 |
| Debt / Equity | -1.6 |
| Total Debt / Capitalization | 267.15 |
| Cash Flow / Debt | -0.67 |
| Interest Coverage | -8.6 |
Financial Efficiency
Return on equity (ROE) is 1.36% and return on capital (ROIC) is -134.31%.
| Return on Equity (ROE) | 1.36% |
| Return on Assets (ROA) | -0.64% |
| Return on Capital (ROIC) | -134.31% |
| Revenue Per Employee | 17.80K |
| Profits Per Employee | -1.24M |
| Employee Count | 423 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.38% in the last 52 weeks. The beta is 0.78, so Cytokinetics's price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | -44.38% |
| 50-Day Moving Average | 50.41 |
| 200-Day Moving Average | 55.73 |
| Relative Strength Index (RSI) | 33.73 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, Cytokinetics had revenue of 7.53M and earned -526.24M in profits. Earnings per share was -5.45.
| Revenue | 7.53M |
| Gross Profit | -322.59M |
| Operating Income | -496.20M |
| Net Income | -526.24M |
| EBITDA | -456.68M |
| EBIT | -496.20M |
| Earnings Per Share (EPS) | -5.45 |
Balance Sheet
The company has 113.02M in cash and 755.77M in debt, giving a net cash position of -642.75M.
| Cash & Cash Equivalents | 113.02M |
| Total Debt | 755.77M |
| Net Cash | -642.75M |
| Retained Earnings | -2.11B |
| Total Assets | 1.44B |
| Working Capital | 908.79M |
Cash Flow
In the last 12 months, operating cash flow was -414.33M and capital expenditures -1.42M, giving a free cash flow of -415.75M.
| Operating Cash Flow | -414.33M |
| Capital Expenditures | -1.42M |
| Free Cash Flow | -415.75M |
| FCF Per Share | -4.31 |
Margins
Gross margin is -4.28K%, with operating and profit margins of -6.59K% and -6.99K%.
| Gross Margin | -4.28K% |
| Operating Margin | -6.59K% |
| Pretax Margin | -6.99K% |
| Profit Margin | -6.99K% |
| EBITDA Margin | -6.06K% |
| EBIT Margin | -6.59K% |
| FCF Margin | -5.52K% |
Dividends & Yields
CYTK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.07% |
| FCF Yield | -7.8% |
Analyst Forecast
The average price target for CYTK is $80, which is 77.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $80 |
| Price Target Difference | 77.1% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
Stock Splits
The last stock split was on Jun 25, 2013. It was a backward split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -0.46 |
| Piotroski F-Score | 3 |